MSTN and type 2 diabetes mellitus: Although loss of muscle mass is a clear clinical feature of type 2 diabetes [14], [15], it is uncertain whether increased circulating myostatin plays a role in the metabolic deterioration of skeletal muscle in individuals with obesity and insulin resistance.